Journal
CLINICAL LYMPHOMA & MYELOMA
Volume 9, Issue 1, Pages 110-112Publisher
CIG MEDIA GROUP, LP
DOI: 10.3816/CLM.2009.n.030
Keywords
Fludarabine; Lymphoplasmacytic lymphoma; Rituximab
Categories
Ask authors/readers for more resources
Recent data on the close association between chronic cold agglutinin disease (CAD) and Waldenstrom's macroglobulinemia (WM) have provided a new potential for therapeutic achievements. In 90% of patients with CAD, the cold agglutinins are monoclonal immunoglobulin M kappa antibodies and clonal lymphocytes can be detected by flow cytometry of bone marrow aspirates. Bone marrow lymphoplasmacytic lymphoma is found by histology and immune histochemistry in 50% of the patients. Thus, CAD represents a spectrum of clonal lymphoproliferative disorders overlapping with WM. Conventional therapies are ineffective. Two prospective trials and 1 population-based retrospective study have shown partial response to rituximab monotherapy in 50%-55%, using strict response criteria. Median response duration was 11 months. We are currently running a prospective, uncontrolled trial of rituximab and fludarabine combination therapy. Although the preliminary results are encouraging, superiority over rituximab monotherapy remains to be proven. Patients with CAD requiring therapy should be included in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available